ASMB

SEC source: 0001209191-22-021772 · doc4.xml · derivative · entry 4

Okazaki Jason A · CIK 0001807214 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,250

Underlying: Common Stock · 31,250 shares

Expires 2027-03-29

F5 · derivative.exercise_price: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

F5 · derivative.exercise_date: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

SEC source: 0001209191-22-021772 · doc4.xml · derivative · entry 3

Okazaki Jason A · CIK 0001807214 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2032-03-29

F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2026.

SEC source: 0001209191-22-021772 · doc4.xml · nonDerivative · entry 1

Okazaki Jason A · CIK 0001807214 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,883

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2023; March 29, 2024; March 29, 2025; and March 29, 2026.

SEC source: 0001209191-22-021781 · doc4.xml · derivative · entry 4

Samar Michael P. · CIK 0001775910 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Common Stock · 26,250 shares

Expires 2027-03-29

F6 · derivative.exercise_price: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

F6 · derivative.exercise_date: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

SEC source: 0001209191-22-021781 · doc4.xml · derivative · entry 3

Samar Michael P. · CIK 0001775910 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 105,000

Underlying: Common Stock · 105,000 shares

Expires 2032-03-29

F5 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2026.

SEC source: 0001209191-22-021781 · doc4.xml · nonDerivative · entry 1

Samar Michael P. · CIK 0001775910 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,033

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2023; March 29, 2024; March 29, 2025; and March 29, 2026.

F2 · balance_after: Includes 1,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan on November 14, 2021.

SEC source: 0001209191-22-021777 · doc4.xml · derivative · entry 4

Stamm Luisa M · CIK 0001793158 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2027-03-29

F5 · derivative.exercise_price: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

F5 · derivative.exercise_date: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

SEC source: 0001209191-22-021777 · doc4.xml · derivative · entry 3

Stamm Luisa M · CIK 0001793158 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2032-03-29

F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2026.

SEC source: 0001209191-22-021777 · doc4.xml · nonDerivative · entry 1

Stamm Luisa M · CIK 0001793158 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,353

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: March 29, 2023; March 29, 2024; March 29, 2025; and March 29, 2026.

SEC source: 0001209191-22-021770 · doc4.xml · derivative · entry 4

McHutchison John G · CIK 0001738125 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,750

Underlying: Common Stock · 83,750 shares

Expires 2027-03-29

F5 · derivative.exercise_price: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

F5 · derivative.exercise_date: Each performance-based restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. The shares are earned if either of two trading price metrics are met (each a "Stock Metric") either on or before the second or on or before the fourth anniversary of the grant date, as applicable. If a Stock Metric is met on or before the first anniversary of the grant date, then 50% of the RSUs vest on the first anniversary of the grant date and the remainder will vest on the second anniversary of the grant date. If a Stock Metric is achieved after the first anniversary of the grant date and on or before the fourth anniversary of the grant date, then 50% of the RSUs vest on the date that the Stock Metric is achieved and the remaining 50% of the RSUs vest on the first anniversary of the initial vesting date. Special vesting provisions apply in the case of a change in control transaction.

SEC source: 0001209191-22-021770 · doc4.xml · derivative · entry 3

McHutchison John G · CIK 0001738125 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,000

Underlying: Common Stock · 335,000 shares

Expires 2032-03-29

F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2023; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2026.

SEC source: 0001209191-22-021770 · doc4.xml · nonDerivative · entry 1

McHutchison John G · CIK 0001738125 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,443

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2023; March 29, 2024; March 29, 2025; and March 29, 2026.

SEC source: 0001209191-22-021535 · doc4.xml · nonDerivative · entry 1

Okazaki Jason A · CIK 0001807214 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,633

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.21 to $2.26, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

F3 · balance_after: Includes an aggregate of 2,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan, with 1,000 shares purchased on May 14, 2021 and 1,000 shares purchased on November 14, 2021.

SEC source: 0001209191-21-050645 · doc4.xml · nonDerivative · entry 1

McHutchison John G · CIK 0001738125 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,693

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.69, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

SEC source: 0001209191-21-047818 · doc4.xml · nonDerivative · entry 1

Samar Michael P. · CIK 0001775910 · SVP, Fin. & Bus. Ops, PFO, PAO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,783

F1 · shares: Grant of restricted stock units. The restricted stock units vest in two equal installments, assuming continuous service on each vesting date, as follows: July 22, 2022 and July 22, 2023.

SEC source: 0001209191-21-047430 · doc4.xml · derivative · entry 1

Houghton Michael · CIK 0001873008 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-07-19

F1 · derivative.exercise_date: Grant of stock options. The stock options vest in three equal installments, assuming continuous service on each vesting date, as follows: July 19, 2022; July 19, 2023; and July 19, 2024.

SEC source: 0001209191-21-036880 · doc4.xml · nonDerivative · entry 1

Delaney William E IV · CIK 0001812734 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,121

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.98 to $4.08, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

F3 · balance_after: Includes 1,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan on May 14, 2021.

SEC source: 0001209191-21-035404 · doc4.xml · derivative · entry 1

Mahony Susan · CIK 0001463321 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-20

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001209191-21-035412 · doc4.xml · derivative · entry 1

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-20

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001209191-21-035400 · doc4.xml · derivative · entry 1

Johnson-Pratt Lisa · CIK 0001849760 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2031-05-20

F1 · derivative.exercise_date: Grant of stock options. The stock options vest in three equal installments, assuming continuous service on each vesting date, as follows: May 20, 2022; May 20, 2023; and May 20, 2024.

SEC source: 0001209191-21-035388 · doc4.xml · derivative · entry 1

HOLUBIAK MYRON Z · CIK 0001199080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-20

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001209191-21-035379 · doc4.xml · derivative · entry 1

DiMarchi Richard D · CIK 0001311733 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-20

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001209191-21-035371 · doc4.xml · derivative · entry 1

Consylman Gina · CIK 0001546358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-20

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001209191-21-035366 · doc4.xml · derivative · entry 1

ALTIG ANTHONY E · CIK 0001215907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-05-20

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) May 20, 2022 and (2) the date of the Issuer's 2022 annual meeting of stockholders.

SEC source: 0001209191-21-024643 · doc4.xml · derivative · entry 2

Delaney William E IV · CIK 0001812734 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2031-03-29

F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025.

SEC source: 0001209191-21-024643 · doc4.xml · nonDerivative · entry 1

Delaney William E IV · CIK 0001812734 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,250

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2022; March 29, 2023; March 29, 2024; and March 29, 2025.

SEC source: 0001209191-21-024631 · doc4.xml · derivative · entry 2

Okazaki Jason A · CIK 0001807214 · Chief Legal & Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,500

Underlying: Common Stock · 82,500 shares

Expires 2031-03-29

F3 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025.

SEC source: 0001209191-21-024631 · doc4.xml · nonDerivative · entry 1

Okazaki Jason A · CIK 0001807214 · Chief Legal & Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,250

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2022; March 29, 2023; March 29, 2024; and March 29, 2025.

F2 · balance_after: Includes 1,000 shares acquired under the Assembly Biosciences, Inc. 2018 Employee Stock Purchase Plan on November 14, 2020.

SEC source: 0001209191-21-024636 · doc4.xml · derivative · entry 2

Russo Thomas Joseph · CIK 0001791973 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2031-03-29

F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025.

SEC source: 0001209191-21-024636 · doc4.xml · nonDerivative · entry 1

Russo Thomas Joseph · CIK 0001791973 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,633

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2022; March 29, 2023; March 29, 2024; and March 29, 2025.

SEC source: 0001209191-21-024640 · doc4.xml · derivative · entry 2

Stamm Luisa M · CIK 0001793158 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2031-03-29

F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025.

SEC source: 0001209191-21-024640 · doc4.xml · nonDerivative · entry 1

Stamm Luisa M · CIK 0001793158 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,853

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four approximately equal installments, assuming continuous service on each vesting date, as follows: March 29, 2022; March 29, 2023; March 29, 2024; and March 29, 2025.

SEC source: 0001209191-21-024621 · doc4.xml · derivative · entry 1

McHutchison John G · CIK 0001738125 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,000

Underlying: Common Stock · 305,000 shares

Expires 2031-03-29

F1 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, March 29, 2022; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2025.

SEC source: 0001209191-20-063666 · doc4.xml · nonDerivative · entry 1

Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,364

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

SEC source: 0001209191-20-057783 · doc4.xml · nonDerivative · entry 1

Stamm Luisa M · CIK 0001793158 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,603

F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.13, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

SEC source: 0001209191-20-055491 · doc4.xml · derivative · entry 1

Consylman Gina · CIK 0001546358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-10-19

F1 · derivative.exercise_date: Grant of stock options. The stock options vest in three approximately equal installments, assuming continuous service on each vesting date, as follows: October 19, 2021; October 19, 2022; and October 19, 2023.

SEC source: 0001209191-20-045952 · doc4.xml · nonDerivative · entry 2

McHutchison John G · CIK 0001738125 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,849

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.39 to $22.62, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

SEC source: 0001209191-20-045952 · doc4.xml · nonDerivative · entry 1

McHutchison John G · CIK 0001738125 · Director · CEO and President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,605

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.38 to $22.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

SEC source: 0001209191-20-036640 · doc4.xml · derivative · entry 1

Mahony Susan · CIK 0001463321 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

SEC source: 0001209191-20-036642 · doc4.xml · derivative · entry 2

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

SEC source: 0001209191-20-036636 · doc4.xml · derivative · entry 1

Kim Helen Susan · CIK 0001422772 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

SEC source: 0001209191-20-036637 · doc4.xml · derivative · entry 1

LEWIS ALAN · CIK 0001207604 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

SEC source: 0001209191-20-036632 · doc4.xml · derivative · entry 1

HOLUBIAK MYRON Z · CIK 0001199080 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

SEC source: 0001209191-20-036630 · doc4.xml · derivative · entry 1

DiMarchi Richard D · CIK 0001311733 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

SEC source: 0001209191-20-036627 · doc4.xml · derivative · entry 1

ALTIG ANTHONY E · CIK 0001215907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2030-06-11

F1 · derivative.exercise_date: Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 11, 2021 and (2) the date of the Issuer's 2021 annual meeting of stockholders.

SEC source: 0001209191-20-032903 · doc4.xml · derivative · entry 2

Delaney William E IV · CIK 0001812734 · CSO, Virology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-05-27

F2 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on the first anniversary of the date of grant, May 27, 2021; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on May 27, 2024.

SEC source: 0001209191-20-032903 · doc4.xml · nonDerivative · entry 1

Delaney William E IV · CIK 0001812734 · CSO, Virology

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

F1 · shares: Grant of restricted stock units. The restricted stock units vest in four equal installments, assuming continuous service on each vesting date, as follows: May 27, 2021; May 27, 2022; May 27, 2023; and May 27, 2024.

SEC source: 0001209191-20-021798 · doc4.xml · nonDerivative · entry 2

Colonno Richard James · CIK 0001663018 · EVP & CSO, Virology Ops

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,009

F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.77 to $15.55, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

SEC source: 0001209191-20-021800 · doc4.xml · nonDerivative · entry 2

Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,661

F2 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.05 to $14.79, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within.

SEC source: 0001209191-20-021800 · doc4.xml · derivative · entry 3

Papkoff Jacqueline Sybil · CIK 0001735729 · SVP-CSO Microbiome

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,000

Underlying: Common Stock · 34,000 shares

Expires 2030-03-27

F4 · derivative.exercise_date: Grant of stock options. The stock options vest over four years, assuming continuous service on each vesting date, as follows: 25% vest on March 29, 2021; and the remaining 75% vest in 36 approximately equal monthly installments, with the options becoming fully vested on March 29, 2024.